Overview
- The White House struck a most-favored-nation pricing agreement with EMD Serono to sell Gonal‑F, Ovidrel and Cetrotide at steep discounts on TrumpRx.gov starting in early 2026, with income-based reductions estimated at 42% to 79% and the company citing up to 84% off when all three drugs are used.
- Labor, Treasury and HHS will issue guidance to let employers offer stand-alone fertility benefits similar to dental or vision coverage, but participation is voluntary and the administration is not mandating coverage or providing subsidies.
- Officials said the FDA will expedite review of Pergoveris, a fertility medicine already available in Europe, as part of the broader effort to expand treatment options in the U.S.
- Administration estimates suggest eligible patients could save roughly $1,200 to $1,900 per IVF cycle on medications, with larger discounts available up to 550% of the federal poverty level, though procedures and lab costs remain separate.
- The package reflects a scaled-back approach compared with President Trump’s 2024 pledge to make IVF free or require insurers to cover it, and prior drug arrangements with Pfizer and AstraZeneca were cited as precedents.